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As light-based control of fundamental signaling pathways is becoming a reality, the ﬁeld of optogenetics is rapidly
moving beyond neuroscience. We have recently developed receptor tyrosine kinases that are activated by light and
control cell proliferation, epithelial–mesenchymal transition, and angiogenic sprouting—cell behaviors central to cancer
progression.
In George Lucas’ epic Star Wars saga,
Jedi knights battle an evil empire with
light sabers. Now, scientists have started
to use light from lasers and light-emitting
diodes to explore new concepts for strik-
ing back at one of humanity’s most threat-
ening foes, cancer.
The concept of optogenetics is based on
genetically encoded effectors of cell signal-
ing that can be rapidly and reversibly acti-
vated by light. Optogenetic approaches
have their roots in neuroscience and date
back more than a decade, when researchers
first managed to control neuronal activity
with light upon introduction of animal
rhodopsin or microbial opsins into a vari-
ety of model organisms. Since then, opto-
genetics has transformed neuroscience
through the dissection of neural circuitry
and brain function in health and disease.1
Over the last few years, the optogenetic
toolkit has expanded dramatically. As a
result, an increasing number of signaling
pathways that are critical for cell fate deci-
sions and hence play major roles in cancer
development and progression became ame-
nable to manipulation by light. For
instance, optically activated variants of son
of sevenless 1, Raf 1, Rho A, Rac 1, phos-
phoinositide 3 kinase p85a, and low-den-
sity lipoprotein receptor-related protein 6
(activating the Wnt pathway) have been
developed and used to study cellular signal-
ing events with an unprecedented degree of
spatial and temporal precision.2
In recent issues of The EMBO Jour-
nal,3 Nature Communications,4 and
Chemistry & Biology,5 collaborative work
from our groups in Austria and work
from the group of Won Do Heo in Korea
independently describe Opto-RTKs,
receptor tyrosine kinases (RTKs) that can
be controlled with light. These reports
demonstrate blue light-induced, spatio-
temporally precise activation of several
members of this crucial cell surface recep-
tor family. Considering the fundamental
role of RTKs in cancer development and
angiogenesis and the clinical importance
of RTK inhibitors, Opto-RTKs hold great
promise for the field of oncology.
RTKs consist of an extracellular ligand-
binding domain, a single-pass transmem-
brane domain, and an intracellular tyro-
sine kinase domain. In Opto-RTKs, the
ligand-mediated dimerization that is
required and sufficient for activation of
many RTKs is replaced with light-induced
dimerization. In all published Opto-
RTKs, light-sensitive protein domains
from diverse non-animal species were
attached to the far C-terminus of the
RTK, whereas the original extracellular
domains were either retained or replaced
by heterologous domains. Our group
screened light oxygen voltage (LOV)
domains of photoreceptors found in
plants, bacteria, and fungi and identified 3
aureochrome LOV domains that are capa-
ble of activating the RTKs murine fibro-
blast growth factor receptor 1 (mFGFR1),
human epidermal growth factor receptor,
and human ret proto-oncogene3
(Fig. 1A). The Heo laboratory used the
photolyase homology region of crypto-
chrome 2 (CRY2) from Arabidopsis thali-
ana to drive the activation of the RTKs
neurotrophin tyrosine kinase receptor
type 1/2/3 (NTRK1/2/3, also known as
tropomyosin-related kinase A/B/C, TrkA/
B/C)4 and human FGFR1.5 The choice of
light-sensing protein domains may have
functional implications as the LOV
domains form dimers,6 whereas CRY2 has
been shown to form oligomeric com-
plexes.7 Importantly, both systems dem-
onstrate light-induced simultaneous
activation of the mitogen activated protein
kinase, phosphoinositide 3 kinase, and
phospholipase Cg pathways, as expected
for canonical RTK signaling and in con-
trast to methods designed for activation of
single pathways. Furthermore, no activa-
tion of signaling in the absence of light is
observed in either of the two systems. We
focused on the role of FGFR1 in
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malignant growth and demonstrated that
light-induced activation of Opto-
mFGFR1 was sufficient to quantitatively
control cell behaviors that are directly rele-
vant to cancer: enhanced proliferation and
epithelial–mesenchymal transition of can-
cer cells, and sprouting of blood endothe-
lial cells.
Using these newly-developed tools,
researchers can now probe the hallmarks of
cancer in new ways to obtain answers to
long-standing questions.8 One focus may lie
in decoding the dynamic intracellular wiring
of signaling pathways and understanding its
link to functional changes in cell behavior.
Repetitive short activation of cellular signal-
ing may result in fundamentally different
outcomes compared to prolonged activa-
tion.9 Also, we have created variants of
Opto-mFGFR1 with mutations in intracel-
lular tyrosine residues that allow us to
restrict activation patterns to specific combi-
nations of downstream effectors. The over-
whelming evidence for RTK
hyperactivation during all stages of cancer
contrasts with the seemingly paradoxical
experience of many researchers that it can be
difficult to overexpress RTKs in untrans-
formed cells and even in fully malignant
cancer cells without triggering apoptosis.
Opto-RTKs may enable detailed studies of
pathway-specific temporal and spatial dose-
effect relationships between RTK activation
and cell fates ranging from proliferation and
migration to differentiation, senescence, and
apoptosis. Figure 1B illustrates possibilities
for spatially or temporally restricted activa-
tion of RTKs in specific loci of living cells,
organotypic co-cultures, or model organ-
isms. Since aberrant RTK signals contribute
tomost functional hallmarks of cancer, these
experiments, combined with rapid and sen-
sitive read-outs of cell signaling and behav-
ior, will lead to a new understanding of key
events underlying cancer in real-time and
with high resolution. In high throughput
formats, similar experiments may signifi-
cantly improve and facilitate drug develop-
ment. We expect that further advances in
the field will create optically controlled
variants of additional RTKs that can also be
activated either simultaneously or separately
(e.g., by light of different colors), and will
enable patterned programming of cell func-
tions and differentiation states with far-
reaching implications in stem cell research
and regenerative medicine. Future studies
will profit from key enabling technologies
that have been established in neuroscience.
These include in vivo illumination technol-
ogy, ranging from surgical implants to trans-
dermal illumination, and 2-photon
excitation approaches.10
There may still be some way to go until
these new tools ultimately benefit applied
research and cancer treatment. Yet, analo-
gous to developments in neuroscience,
subsequent episodes in which researchers
use Opto-RTKs for new discoveries in the
field of oncology will soon follow.
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Figure 1. Recently published optically controlled receptor tyrosine kinases (Opto-RTKs) and potential applications in cellular oncology. (A) Design princi-
ples of the ﬁrst Opto-RTKs recently described by our groups in Austria and the group in Korea and accessible cellular functions. Manipulated RTKs include
murine/human ﬁbroblast growth factor receptor 1 (m/hFGFR1), human epidermal growth factor receptor (hEGFR), human ret proto-oncogene (hRET),
and tropomyosin-related kinase A/B/C (TrkA/B/C). Activation was achieved through attaching light oxygen voltage (LOV) domains of V. frigida aureo-
chrome 1 (VfAU1) or O. danica/N. gaditana putative aureochrome 1 (Od/NgPA1) to the intracellular domains (ID) of the receptors. Extracellular (ED) and
transmembrane domains (TD) were either retained or removed. Fluorescent proteins such as mCitrine (Ci) can be further added to the protein. (B) Opto-
RTKs can be used to test the effects of temporally or spatially deﬁned signaling patterns on cancer-related functions. By (co-)expressing Opto-RTKs that
respond to light of different color (depicted in blue and red) in speciﬁc cell types (e.g., epithelial cells, ﬁbroblasts, endothelial cells, immune cells), an
additional level of control can be achieved. Hallmark characteristics linked to cell functions that were manipulated by light via Opto-RTKs in the recent
publications are highlighted.
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